Leobendorf, Austria (OTE) – Saypha® injectables to launch in the U.S.
under the Obagi Medical
brand, expanding global reach of Croma’s science-driven aesthetic
solutions
Croma-Pharma GmbH, a global leader in minimally invasive
aesthetic medicine, today announced the acquisition of Novaestiq
Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture
between Croma-Pharma and Gore Range Capital, is the company behind
the innovative Saypha® ChIQ™ and Saypha® MagIQ™ injectable hyaluronic
acid gels, which are set to launch in the U.S. under the Obagi
Medical brand.
This transaction marks a key milestone in Croma-Pharma’s
international growth strategy and reinforces its commitment to
providing scientifically validated, high-quality products for the
global aesthetic market.
„We are thrilled to see Novaestiq join forces with Waldencast, a
move that amplifies our shared commitment to advancing aesthetic
medicine,“ said Andreas Prinz, CEO of Croma-Pharma GmbH. „The
introduction of Saypha® ChIQ™and MagIQ™ to the U.S. market under the
Obagi Medical brand marks a significant step in delivering
innovative, science-driven aesthetic solutions to patients
worldwide.“
Saypha®, developed and manufactured by Croma-Pharma, is a
globally recognized line of hyaluronic acid (HA) injectables known
for their safety, efficacy, and high patient satisfaction. With over
40 years of experience in HA products, Croma-Pharma has produced more
than 110 million syringes to date, and its fillers are approved in
over 80 markets worldwide. The company maintains a dedicated focus on
aesthetic medicine and offers a broad portfolio of minimally invasive
treatments.
The upcoming U.S. launch of Saypha® injectables, currently
undergoing the FDA approval process,1 is supported by a robust
clinical program, including pivotal studies that exceed industry
standards in size and diversity. These trials reflect Obagi Medical’s
and Croma-Pharma’s shared commitment to inclusivity and scientific
excellence in aesthetic care.
„This partnership is a testament to the strength of our
innovation pipeline and our ability to collaborate with visionary
partners,“ added Prinz. „We are confident that Waldencast and Obagi
Medical will successfully bring Saypha® to a new generation of U.S.
physicians and patients.“
About Croma-Pharma GmbH
Founded in 1976, Croma-Pharma GmbH is a family-owned global
player in the field of minimally invasive aesthetic medicine.
Headquartered in Leobendorf, Austria, the company specializes in the
industrial production of hyaluronic acid syringes and distributes its
products in more than 80 countries. Croma offers a comprehensive
aesthetics portfolio including HA fillers, botulinum toxin, PDO
threads, and biostimulators. Learn more at www.croma.at .
About Waldencast
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition
is to build a global best-in-class beauty and wellness operating
platform by developing, acquiring, accelerating, and scaling
conscious, high-growth purpose-driven brands. Waldencast’s vision is
fundamentally underpinned by its brand-led business model that
ensures proximity to its customers, business agility, and market
responsiveness, while maintaining each brand’s distinct DNA. The
first step in realizing its vision was the business combination with
Obagi Medical and Milk Makeup. As part of the Waldencast platform,
its brands will benefit from the operational scale of a multi-brand
platform; the expertise in managing global beauty brands at scale; a
balanced portfolio to mitigate category fluctuations; asset light
efficiency; and the market responsiveness and speed of
entrepreneurial indie brands. For more information please visit:
https://ir.waldencast.com/ .
About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line
rooted in research and skin biology, with a legacy of 35+ years of
experience. Initially known for its leadership in the treatment of
hyperpigmentation with the Obagi Nu-Derm® System, Obagi Medical
products are designed to address a variety of skin concerns,
including premature aging, photodamage, skin discoloration, acne, and
sun damage. As the fastest-growing professional skincare brand in the
U.S. in 2024,2 Obagi Medical empowers individuals to achieve healthy,
beautiful skin. More information about Obagi Medical is available on
the brand’s website, https://www.obagi.com .
About Gore Range Capital
Gore Range Capital is a committed investor in innovation and
excellence in skin health. With a focus on creating impactful medical
solutions, Gore Range Capital continues to pave the way for next-
generation products that offer transformative results for physicians,
patients and consumers. Until this transaction, Novaestiq was a joint
-venture between Croma Pharma and Gore Range Capital that developed
dermal fillers for the North American market. Learn more at:
https://www.gorerangecapital.com/ .
1Saypha® products are not approved medical devices, and each
product has a premarket approval (PMA) application under review by
the FDA. 2 Among the Top 10 Professional Skin Care Brands in the
U.S., According to Kline’s 2024 Global Professional Skin Care Series
(China, Europe and the U.S.).
www.cromapharma.com
Digital press kit: http://www.ots.at/pressemappe/PR180407/aom